Safety and immunogenicity of the COVID-19 vaccine BNT162b2 for patients with breast and gynecological cancer on active anticancer therapy: Results of a prospective observational study

Safety and immunogenicity of the COVID-19 vaccine BNT162b2 for patients with breast and gynecological cancer on active anticancer therapy: Results of a prospective observational study

BackgroundVaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are highly effective. Nevertheless, immunocompromised participants were excluded from randomized controlled clinical trials. This study evaluates the efficacy and safety of the Pfizer/BioNTech BNT162b2 (BNT162b2)...

Full description

Bibliographic Details
Main Authors: Pietro De Placido, Erica Pietroluongo, Carmine De Angelis, Margherita Tafuro, Chiara Barraco, Rosa Giannatiempo, Roberto Buonaiuto, Francesco Schettini, Anna Iervolino, Emilia Anna Vozzella, Mario Giuliano, Roberto Bianco, Grazia Arpino
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-08-01
Series:Frontiers in Oncology
Subjects:
COVID - 19
BNT162b2
COVID vaccine
breast cancer
chemotherapy
target therapies
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.951026/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.951026/full

Similar Items